PMC:7172841 / 22547-24252 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T135","span":{"begin":104,"end":109},"obj":"Body_part"},{"id":"T136","span":{"begin":174,"end":183},"obj":"Body_part"},{"id":"T137","span":{"begin":311,"end":321},"obj":"Body_part"},{"id":"T138","span":{"begin":372,"end":381},"obj":"Body_part"},{"id":"T139","span":{"begin":514,"end":523},"obj":"Body_part"},{"id":"T140","span":{"begin":648,"end":654},"obj":"Body_part"},{"id":"T141","span":{"begin":682,"end":685},"obj":"Body_part"},{"id":"T142","span":{"begin":697,"end":706},"obj":"Body_part"},{"id":"T143","span":{"begin":831,"end":837},"obj":"Body_part"},{"id":"T144","span":{"begin":894,"end":903},"obj":"Body_part"},{"id":"T145","span":{"begin":1010,"end":1016},"obj":"Body_part"},{"id":"T146","span":{"begin":1127,"end":1130},"obj":"Body_part"},{"id":"T147","span":{"begin":1142,"end":1151},"obj":"Body_part"},{"id":"T148","span":{"begin":1258,"end":1264},"obj":"Body_part"},{"id":"T149","span":{"begin":1377,"end":1387},"obj":"Body_part"},{"id":"T150","span":{"begin":1508,"end":1517},"obj":"Body_part"},{"id":"T151","span":{"begin":1529,"end":1540},"obj":"Body_part"}],"attributes":[{"id":"A135","pred":"fma_id","subj":"T135","obj":"http://purl.org/sig/ont/fma/fma63083"},{"id":"A136","pred":"fma_id","subj":"T136","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A137","pred":"fma_id","subj":"T137","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A138","pred":"fma_id","subj":"T138","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A139","pred":"fma_id","subj":"T139","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A140","pred":"fma_id","subj":"T140","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A141","pred":"fma_id","subj":"T141","obj":"http://purl.org/sig/ont/fma/fma84795"},{"id":"A142","pred":"fma_id","subj":"T142","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A143","pred":"fma_id","subj":"T143","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A144","pred":"fma_id","subj":"T144","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A145","pred":"fma_id","subj":"T145","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A146","pred":"fma_id","subj":"T146","obj":"http://purl.org/sig/ont/fma/fma84795"},{"id":"A147","pred":"fma_id","subj":"T147","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A148","pred":"fma_id","subj":"T148","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A149","pred":"fma_id","subj":"T149","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A150","pred":"fma_id","subj":"T150","obj":"http://purl.org/sig/ont/fma/fma62864"},{"id":"A151","pred":"fma_id","subj":"T151","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"Figure 5 Immune Dysregulation Caused by SARS-CoV-2 Is Mediated by IL-6\n(A) Negative correlation between serum amounts of IL-6 and the absolute numbers of the mHLA-DR on CD14 monocytes. The Spearman’s (rs) co-efficient of correlation and the respective p value are provided.\n(B) Correlation between the absolute lymphocyte count and the absolute numbers of mHLA-DR on CD14 monocytes. The rs co-efficient of correlation and the respective p value are provided.\n(C) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(D) Changes of the MFI of HLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(E) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker Tocilizumab is also shown.\n(F) Changes of the MFI of HLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker tocilizumab is also shown.\n(G) Changes of the absolute lymphocyte count of six patients before and after start of treatment with Tocilizumab.\n(H) Intracellular staining for IL-6 in CD14 monocytes and in CD4 lymphocytes of three patients infected by SARS-CoV-2 with immune dysregulation.\nStatistical comparisons are indicated by the arrows; ns: non-significant; ∗p \u003c 0.05; ∗∗p \u003c 0.01."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T17","span":{"begin":104,"end":109},"obj":"Body_part"}],"attributes":[{"id":"A17","pred":"uberon_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"Figure 5 Immune Dysregulation Caused by SARS-CoV-2 Is Mediated by IL-6\n(A) Negative correlation between serum amounts of IL-6 and the absolute numbers of the mHLA-DR on CD14 monocytes. The Spearman’s (rs) co-efficient of correlation and the respective p value are provided.\n(B) Correlation between the absolute lymphocyte count and the absolute numbers of mHLA-DR on CD14 monocytes. The rs co-efficient of correlation and the respective p value are provided.\n(C) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(D) Changes of the MFI of HLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(E) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker Tocilizumab is also shown.\n(F) Changes of the MFI of HLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker tocilizumab is also shown.\n(G) Changes of the absolute lymphocyte count of six patients before and after start of treatment with Tocilizumab.\n(H) Intracellular staining for IL-6 in CD14 monocytes and in CD4 lymphocytes of three patients infected by SARS-CoV-2 with immune dysregulation.\nStatistical comparisons are indicated by the arrows; ns: non-significant; ∗p \u003c 0.05; ∗∗p \u003c 0.01."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T206","span":{"begin":40,"end":48},"obj":"Disease"},{"id":"T207","span":{"begin":40,"end":44},"obj":"Disease"},{"id":"T208","span":{"begin":553,"end":561},"obj":"Disease"},{"id":"T209","span":{"begin":553,"end":557},"obj":"Disease"},{"id":"T210","span":{"begin":736,"end":744},"obj":"Disease"},{"id":"T211","span":{"begin":736,"end":740},"obj":"Disease"},{"id":"T212","span":{"begin":934,"end":942},"obj":"Disease"},{"id":"T213","span":{"begin":934,"end":938},"obj":"Disease"},{"id":"T214","span":{"begin":1182,"end":1190},"obj":"Disease"},{"id":"T215","span":{"begin":1182,"end":1186},"obj":"Disease"},{"id":"T216","span":{"begin":1571,"end":1579},"obj":"Disease"},{"id":"T217","span":{"begin":1571,"end":1575},"obj":"Disease"}],"attributes":[{"id":"A206","pred":"mondo_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A207","pred":"mondo_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A208","pred":"mondo_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A209","pred":"mondo_id","subj":"T209","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A210","pred":"mondo_id","subj":"T210","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A211","pred":"mondo_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A212","pred":"mondo_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A213","pred":"mondo_id","subj":"T213","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A214","pred":"mondo_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A215","pred":"mondo_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A216","pred":"mondo_id","subj":"T216","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A217","pred":"mondo_id","subj":"T217","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Figure 5 Immune Dysregulation Caused by SARS-CoV-2 Is Mediated by IL-6\n(A) Negative correlation between serum amounts of IL-6 and the absolute numbers of the mHLA-DR on CD14 monocytes. The Spearman’s (rs) co-efficient of correlation and the respective p value are provided.\n(B) Correlation between the absolute lymphocyte count and the absolute numbers of mHLA-DR on CD14 monocytes. The rs co-efficient of correlation and the respective p value are provided.\n(C) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(D) Changes of the MFI of HLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(E) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker Tocilizumab is also shown.\n(F) Changes of the MFI of HLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker tocilizumab is also shown.\n(G) Changes of the absolute lymphocyte count of six patients before and after start of treatment with Tocilizumab.\n(H) Intracellular staining for IL-6 in CD14 monocytes and in CD4 lymphocytes of three patients infected by SARS-CoV-2 with immune dysregulation.\nStatistical comparisons are indicated by the arrows; ns: non-significant; ∗p \u003c 0.05; ∗∗p \u003c 0.01."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T201","span":{"begin":72,"end":73},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T202","span":{"begin":174,"end":183},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T203","span":{"begin":201,"end":203},"obj":"http://purl.obolibrary.org/obo/CLO_0008882"},{"id":"T204","span":{"begin":275,"end":276},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T205","span":{"begin":372,"end":381},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T206","span":{"begin":387,"end":389},"obj":"http://purl.obolibrary.org/obo/CLO_0008882"},{"id":"T207","span":{"begin":514,"end":523},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T208","span":{"begin":598,"end":608},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T209","span":{"begin":648,"end":654},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T210","span":{"begin":697,"end":706},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T211","span":{"begin":781,"end":791},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T212","span":{"begin":831,"end":837},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T213","span":{"begin":894,"end":903},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T214","span":{"begin":1010,"end":1016},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T215","span":{"begin":1142,"end":1151},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T216","span":{"begin":1258,"end":1264},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T217","span":{"begin":1508,"end":1517},"obj":"http://purl.obolibrary.org/obo/CL_0000576"},{"id":"T218","span":{"begin":1525,"end":1528},"obj":"http://purl.obolibrary.org/obo/PR_000001004"}],"text":"Figure 5 Immune Dysregulation Caused by SARS-CoV-2 Is Mediated by IL-6\n(A) Negative correlation between serum amounts of IL-6 and the absolute numbers of the mHLA-DR on CD14 monocytes. The Spearman’s (rs) co-efficient of correlation and the respective p value are provided.\n(B) Correlation between the absolute lymphocyte count and the absolute numbers of mHLA-DR on CD14 monocytes. The rs co-efficient of correlation and the respective p value are provided.\n(C) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(D) Changes of the MFI of HLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(E) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker Tocilizumab is also shown.\n(F) Changes of the MFI of HLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker tocilizumab is also shown.\n(G) Changes of the absolute lymphocyte count of six patients before and after start of treatment with Tocilizumab.\n(H) Intracellular staining for IL-6 in CD14 monocytes and in CD4 lymphocytes of three patients infected by SARS-CoV-2 with immune dysregulation.\nStatistical comparisons are indicated by the arrows; ns: non-significant; ∗p \u003c 0.05; ∗∗p \u003c 0.01."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T127","span":{"begin":66,"end":68},"obj":"Chemical"},{"id":"T129","span":{"begin":121,"end":123},"obj":"Chemical"},{"id":"T131","span":{"begin":163,"end":165},"obj":"Chemical"},{"id":"T132","span":{"begin":361,"end":363},"obj":"Chemical"},{"id":"T133","span":{"begin":503,"end":505},"obj":"Chemical"},{"id":"T134","span":{"begin":686,"end":688},"obj":"Chemical"},{"id":"T135","span":{"begin":883,"end":885},"obj":"Chemical"},{"id":"T136","span":{"begin":1061,"end":1063},"obj":"Chemical"},{"id":"T138","span":{"begin":1131,"end":1133},"obj":"Chemical"},{"id":"T139","span":{"begin":1309,"end":1311},"obj":"Chemical"},{"id":"T141","span":{"begin":1322,"end":1333},"obj":"Chemical"},{"id":"T142","span":{"begin":1495,"end":1497},"obj":"Chemical"}],"attributes":[{"id":"A127","pred":"chebi_id","subj":"T127","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A128","pred":"chebi_id","subj":"T127","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A129","pred":"chebi_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A130","pred":"chebi_id","subj":"T129","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A131","pred":"chebi_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"},{"id":"A132","pred":"chebi_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"},{"id":"A133","pred":"chebi_id","subj":"T133","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"},{"id":"A134","pred":"chebi_id","subj":"T134","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"},{"id":"A135","pred":"chebi_id","subj":"T135","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"},{"id":"A136","pred":"chebi_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A137","pred":"chebi_id","subj":"T136","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A138","pred":"chebi_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"},{"id":"A139","pred":"chebi_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A140","pred":"chebi_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A141","pred":"chebi_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A142","pred":"chebi_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A143","pred":"chebi_id","subj":"T142","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"Figure 5 Immune Dysregulation Caused by SARS-CoV-2 Is Mediated by IL-6\n(A) Negative correlation between serum amounts of IL-6 and the absolute numbers of the mHLA-DR on CD14 monocytes. The Spearman’s (rs) co-efficient of correlation and the respective p value are provided.\n(B) Correlation between the absolute lymphocyte count and the absolute numbers of mHLA-DR on CD14 monocytes. The rs co-efficient of correlation and the respective p value are provided.\n(C) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(D) Changes of the MFI of HLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(E) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker Tocilizumab is also shown.\n(F) Changes of the MFI of HLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker tocilizumab is also shown.\n(G) Changes of the absolute lymphocyte count of six patients before and after start of treatment with Tocilizumab.\n(H) Intracellular staining for IL-6 in CD14 monocytes and in CD4 lymphocytes of three patients infected by SARS-CoV-2 with immune dysregulation.\nStatistical comparisons are indicated by the arrows; ns: non-significant; ∗p \u003c 0.05; ∗∗p \u003c 0.01."}

{"project":"LitCovid-sentences","denotations":[{"id":"T167","span":{"begin":0,"end":70},"obj":"Sentence"},{"id":"T168","span":{"begin":71,"end":184},"obj":"Sentence"},{"id":"T169","span":{"begin":185,"end":273},"obj":"Sentence"},{"id":"T170","span":{"begin":274,"end":382},"obj":"Sentence"},{"id":"T171","span":{"begin":383,"end":458},"obj":"Sentence"},{"id":"T172","span":{"begin":459,"end":655},"obj":"Sentence"},{"id":"T173","span":{"begin":656,"end":838},"obj":"Sentence"},{"id":"T174","span":{"begin":839,"end":1100},"obj":"Sentence"},{"id":"T175","span":{"begin":1101,"end":1348},"obj":"Sentence"},{"id":"T176","span":{"begin":1349,"end":1463},"obj":"Sentence"},{"id":"T177","span":{"begin":1464,"end":1608},"obj":"Sentence"},{"id":"T178","span":{"begin":1609,"end":1705},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Figure 5 Immune Dysregulation Caused by SARS-CoV-2 Is Mediated by IL-6\n(A) Negative correlation between serum amounts of IL-6 and the absolute numbers of the mHLA-DR on CD14 monocytes. The Spearman’s (rs) co-efficient of correlation and the respective p value are provided.\n(B) Correlation between the absolute lymphocyte count and the absolute numbers of mHLA-DR on CD14 monocytes. The rs co-efficient of correlation and the respective p value are provided.\n(C) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(D) Changes of the MFI of HLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(E) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker Tocilizumab is also shown.\n(F) Changes of the MFI of HLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker tocilizumab is also shown.\n(G) Changes of the absolute lymphocyte count of six patients before and after start of treatment with Tocilizumab.\n(H) Intracellular staining for IL-6 in CD14 monocytes and in CD4 lymphocytes of three patients infected by SARS-CoV-2 with immune dysregulation.\nStatistical comparisons are indicated by the arrows; ns: non-significant; ∗p \u003c 0.05; ∗∗p \u003c 0.01."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T82","span":{"begin":9,"end":29},"obj":"Phenotype"},{"id":"T83","span":{"begin":950,"end":970},"obj":"Phenotype"},{"id":"T84","span":{"begin":1198,"end":1218},"obj":"Phenotype"},{"id":"T85","span":{"begin":1587,"end":1607},"obj":"Phenotype"}],"attributes":[{"id":"A82","pred":"hp_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/HP_0002958"},{"id":"A83","pred":"hp_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/HP_0002958"},{"id":"A84","pred":"hp_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/HP_0002958"},{"id":"A85","pred":"hp_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/HP_0002958"}],"text":"Figure 5 Immune Dysregulation Caused by SARS-CoV-2 Is Mediated by IL-6\n(A) Negative correlation between serum amounts of IL-6 and the absolute numbers of the mHLA-DR on CD14 monocytes. The Spearman’s (rs) co-efficient of correlation and the respective p value are provided.\n(B) Correlation between the absolute lymphocyte count and the absolute numbers of mHLA-DR on CD14 monocytes. The rs co-efficient of correlation and the respective p value are provided.\n(C) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(D) Changes of the MFI of HLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(E) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker Tocilizumab is also shown.\n(F) Changes of the MFI of HLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker tocilizumab is also shown.\n(G) Changes of the absolute lymphocyte count of six patients before and after start of treatment with Tocilizumab.\n(H) Intracellular staining for IL-6 in CD14 monocytes and in CD4 lymphocytes of three patients infected by SARS-CoV-2 with immune dysregulation.\nStatistical comparisons are indicated by the arrows; ns: non-significant; ∗p \u003c 0.05; ∗∗p \u003c 0.01."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T671","span":{"begin":16,"end":29},"obj":"GO:0065007"},{"id":"T672","span":{"begin":40,"end":50},"obj":"SP_7"},{"id":"T673","span":{"begin":66,"end":70},"obj":"PR:000001393"},{"id":"T674","span":{"begin":104,"end":109},"obj":"UBERON:0001977"},{"id":"T675","span":{"begin":121,"end":125},"obj":"PR:000001393"},{"id":"T676","span":{"begin":169,"end":173},"obj":"PR:000001889"},{"id":"T677","span":{"begin":174,"end":183},"obj":"CL:0000576"},{"id":"T678","span":{"begin":311,"end":321},"obj":"CL:0000542"},{"id":"T679","span":{"begin":367,"end":371},"obj":"PR:000001889"},{"id":"T680","span":{"begin":372,"end":381},"obj":"CL:0000576"},{"id":"T681","span":{"begin":509,"end":513},"obj":"PR:000001889"},{"id":"T682","span":{"begin":514,"end":523},"obj":"CL:0000576"},{"id":"T683","span":{"begin":553,"end":563},"obj":"SP_7"},{"id":"T684","span":{"begin":591,"end":597},"obj":"UBERON:0002405"},{"id":"T685","span":{"begin":648,"end":654},"obj":"UBERON:0001969"},{"id":"T686","span":{"begin":675,"end":678},"obj":"GO:0005675"},{"id":"T687","span":{"begin":682,"end":685},"obj":"PR:000029150"},{"id":"T688","span":{"begin":692,"end":696},"obj":"PR:000001889"},{"id":"T689","span":{"begin":697,"end":706},"obj":"CL:0000576"},{"id":"T690","span":{"begin":736,"end":746},"obj":"SP_7"},{"id":"T691","span":{"begin":774,"end":780},"obj":"UBERON:0002405"},{"id":"T692","span":{"begin":831,"end":837},"obj":"UBERON:0001969"},{"id":"T693","span":{"begin":889,"end":893},"obj":"PR:000001889"},{"id":"T694","span":{"begin":894,"end":903},"obj":"CL:0000576"},{"id":"T695","span":{"begin":934,"end":944},"obj":"SP_7"},{"id":"T696","span":{"begin":950,"end":956},"obj":"UBERON:0002405"},{"id":"T697","span":{"begin":957,"end":970},"obj":"GO:0065007"},{"id":"T698","span":{"begin":1010,"end":1016},"obj":"UBERON:0001969"},{"id":"T699","span":{"begin":1018,"end":1028},"obj":"GO:0065007"},{"id":"T700","span":{"begin":1061,"end":1065},"obj":"PR:000001393"},{"id":"T701","span":{"begin":1074,"end":1085},"obj":"DG_35"},{"id":"T702","span":{"begin":1127,"end":1130},"obj":"PR:000029150"},{"id":"T703","span":{"begin":1137,"end":1141},"obj":"PR:000001889"},{"id":"T704","span":{"begin":1142,"end":1151},"obj":"CL:0000576"},{"id":"T705","span":{"begin":1182,"end":1192},"obj":"SP_7"},{"id":"T706","span":{"begin":1198,"end":1204},"obj":"UBERON:0002405"},{"id":"T707","span":{"begin":1205,"end":1218},"obj":"GO:0065007"},{"id":"T708","span":{"begin":1258,"end":1264},"obj":"UBERON:0001969"},{"id":"T709","span":{"begin":1266,"end":1276},"obj":"GO:0065007"},{"id":"T710","span":{"begin":1309,"end":1313},"obj":"PR:000001393"},{"id":"T711","span":{"begin":1322,"end":1333},"obj":"DG_35"},{"id":"T712","span":{"begin":1377,"end":1387},"obj":"CL:0000542"},{"id":"T713","span":{"begin":1451,"end":1462},"obj":"DG_35"},{"id":"T714","span":{"begin":1468,"end":1481},"obj":"GO:0005622"},{"id":"T715","span":{"begin":1495,"end":1499},"obj":"PR:000001393"},{"id":"T716","span":{"begin":1503,"end":1507},"obj":"PR:000001889"},{"id":"T717","span":{"begin":1508,"end":1517},"obj":"CL:0000576"},{"id":"T718","span":{"begin":1525,"end":1528},"obj":"PR:000001004"},{"id":"T719","span":{"begin":1529,"end":1540},"obj":"CL:0000542"},{"id":"T720","span":{"begin":1571,"end":1581},"obj":"SP_7"},{"id":"T721","span":{"begin":1587,"end":1593},"obj":"UBERON:0002405"},{"id":"T722","span":{"begin":1594,"end":1607},"obj":"GO:0065007"},{"id":"T723","span":{"begin":136,"end":147},"obj":"SP_7"},{"id":"T724","span":{"begin":163,"end":167},"obj":"PR:000001393"},{"id":"T725","span":{"begin":201,"end":206},"obj":"UBERON:0001977"},{"id":"T726","span":{"begin":218,"end":222},"obj":"PR:000001393"},{"id":"T727","span":{"begin":265,"end":269},"obj":"PR:000001889"},{"id":"T728","span":{"begin":270,"end":279},"obj":"CL:0000576"},{"id":"T729","span":{"begin":408,"end":418},"obj":"CL:0000542"},{"id":"T730","span":{"begin":463,"end":467},"obj":"PR:000001889"},{"id":"T731","span":{"begin":468,"end":477},"obj":"CL:0000576"},{"id":"T732","span":{"begin":606,"end":610},"obj":"PR:000001889"},{"id":"T733","span":{"begin":611,"end":620},"obj":"CL:0000576"},{"id":"T734","span":{"begin":650,"end":660},"obj":"SP_7"},{"id":"T735","span":{"begin":688,"end":693},"obj":"UBERON:0002405"},{"id":"T736","span":{"begin":744,"end":750},"obj":"UBERON:0001969"},{"id":"T737","span":{"begin":771,"end":774},"obj":"GO:0005675"},{"id":"T738","span":{"begin":779,"end":782},"obj":"PR:000029150"},{"id":"T739","span":{"begin":789,"end":793},"obj":"PR:000001889"},{"id":"T740","span":{"begin":794,"end":803},"obj":"CL:0000576"},{"id":"T741","span":{"begin":833,"end":843},"obj":"SP_7"},{"id":"T742","span":{"begin":872,"end":877},"obj":"UBERON:0002405"},{"id":"T743","span":{"begin":928,"end":934},"obj":"UBERON:0001969"},{"id":"T744","span":{"begin":986,"end":990},"obj":"PR:000001889"},{"id":"T745","span":{"begin":991,"end":1000},"obj":"CL:0000576"},{"id":"T746","span":{"begin":1031,"end":1041},"obj":"SP_7"},{"id":"T747","span":{"begin":1047,"end":1052},"obj":"UBERON:0002405"},{"id":"T748","span":{"begin":1053,"end":1066},"obj":"GO:0065007"},{"id":"T749","span":{"begin":1106,"end":1112},"obj":"UBERON:0001969"},{"id":"T750","span":{"begin":1114,"end":1124},"obj":"GO:0065007"},{"id":"T751","span":{"begin":1157,"end":1161},"obj":"PR:000001393"},{"id":"T752","span":{"begin":1170,"end":1181},"obj":"DG_35"},{"id":"T753","span":{"begin":1224,"end":1227},"obj":"PR:000029150"},{"id":"T754","span":{"begin":1234,"end":1238},"obj":"PR:000001889"},{"id":"T755","span":{"begin":1239,"end":1248},"obj":"CL:0000576"},{"id":"T756","span":{"begin":1279,"end":1289},"obj":"SP_7"},{"id":"T757","span":{"begin":1295,"end":1300},"obj":"UBERON:0002405"},{"id":"T758","span":{"begin":1301,"end":1314},"obj":"GO:0065007"},{"id":"T759","span":{"begin":1354,"end":1360},"obj":"UBERON:0001969"},{"id":"T760","span":{"begin":1362,"end":1372},"obj":"GO:0065007"},{"id":"T761","span":{"begin":1405,"end":1409},"obj":"PR:000001393"},{"id":"T762","span":{"begin":1418,"end":1429},"obj":"DG_35"},{"id":"T763","span":{"begin":1473,"end":1483},"obj":"CL:0000542"},{"id":"T764","span":{"begin":1547,"end":1558},"obj":"DG_35"},{"id":"T765","span":{"begin":1564,"end":1577},"obj":"GO:0005622"},{"id":"T766","span":{"begin":1592,"end":1596},"obj":"PR:000001393"},{"id":"T767","span":{"begin":1600,"end":1604},"obj":"PR:000001889"},{"id":"T768","span":{"begin":1605,"end":1614},"obj":"CL:0000576"},{"id":"T769","span":{"begin":1622,"end":1625},"obj":"PR:000001004"},{"id":"T770","span":{"begin":1626,"end":1637},"obj":"CL:0000542"},{"id":"T771","span":{"begin":1668,"end":1678},"obj":"SP_7"},{"id":"T772","span":{"begin":1684,"end":1689},"obj":"UBERON:0002405"},{"id":"T773","span":{"begin":1690,"end":1703},"obj":"GO:0065007"}],"text":"Figure 5 Immune Dysregulation Caused by SARS-CoV-2 Is Mediated by IL-6\n(A) Negative correlation between serum amounts of IL-6 and the absolute numbers of the mHLA-DR on CD14 monocytes. The Spearman’s (rs) co-efficient of correlation and the respective p value are provided.\n(B) Correlation between the absolute lymphocyte count and the absolute numbers of mHLA-DR on CD14 monocytes. The rs co-efficient of correlation and the respective p value are provided.\n(C) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(D) Changes of the MFI of HLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(E) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker Tocilizumab is also shown.\n(F) Changes of the MFI of HLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker tocilizumab is also shown.\n(G) Changes of the absolute lymphocyte count of six patients before and after start of treatment with Tocilizumab.\n(H) Intracellular staining for IL-6 in CD14 monocytes and in CD4 lymphocytes of three patients infected by SARS-CoV-2 with immune dysregulation.\nStatistical comparisons are indicated by the arrows; ns: non-significant; ∗p \u003c 0.05; ∗∗p \u003c 0.01."}

{"project":"LitCovid-PubTator","denotations":[{"id":"849","span":{"begin":40,"end":50},"obj":"Species"},{"id":"852","span":{"begin":121,"end":125},"obj":"Gene"},{"id":"853","span":{"begin":169,"end":173},"obj":"Gene"},{"id":"855","span":{"begin":367,"end":371},"obj":"Gene"},{"id":"860","span":{"begin":509,"end":513},"obj":"Gene"},{"id":"861","span":{"begin":532,"end":540},"obj":"Species"},{"id":"862","span":{"begin":553,"end":563},"obj":"Species"},{"id":"863","span":{"begin":541,"end":549},"obj":"Disease"},{"id":"868","span":{"begin":692,"end":696},"obj":"Gene"},{"id":"869","span":{"begin":715,"end":723},"obj":"Species"},{"id":"870","span":{"begin":736,"end":746},"obj":"Species"},{"id":"871","span":{"begin":724,"end":732},"obj":"Disease"},{"id":"878","span":{"begin":889,"end":893},"obj":"Gene"},{"id":"879","span":{"begin":1061,"end":1065},"obj":"Gene"},{"id":"880","span":{"begin":913,"end":921},"obj":"Species"},{"id":"881","span":{"begin":934,"end":944},"obj":"Species"},{"id":"882","span":{"begin":1074,"end":1085},"obj":"Chemical"},{"id":"883","span":{"begin":922,"end":930},"obj":"Disease"},{"id":"890","span":{"begin":1137,"end":1141},"obj":"Gene"},{"id":"891","span":{"begin":1309,"end":1313},"obj":"Gene"},{"id":"892","span":{"begin":1161,"end":1169},"obj":"Species"},{"id":"893","span":{"begin":1182,"end":1192},"obj":"Species"},{"id":"894","span":{"begin":1322,"end":1333},"obj":"Chemical"},{"id":"895","span":{"begin":1170,"end":1178},"obj":"Disease"},{"id":"898","span":{"begin":1401,"end":1409},"obj":"Species"},{"id":"899","span":{"begin":1451,"end":1462},"obj":"Chemical"},{"id":"906","span":{"begin":1495,"end":1499},"obj":"Gene"},{"id":"907","span":{"begin":1503,"end":1507},"obj":"Gene"},{"id":"908","span":{"begin":1525,"end":1528},"obj":"Gene"},{"id":"909","span":{"begin":1550,"end":1558},"obj":"Species"},{"id":"910","span":{"begin":1571,"end":1581},"obj":"Species"},{"id":"911","span":{"begin":1559,"end":1567},"obj":"Disease"}],"attributes":[{"id":"A849","pred":"tao:has_database_id","subj":"849","obj":"Tax:2697049"},{"id":"A852","pred":"tao:has_database_id","subj":"852","obj":"Gene:3569"},{"id":"A853","pred":"tao:has_database_id","subj":"853","obj":"Gene:929"},{"id":"A855","pred":"tao:has_database_id","subj":"855","obj":"Gene:929"},{"id":"A860","pred":"tao:has_database_id","subj":"860","obj":"Gene:929"},{"id":"A861","pred":"tao:has_database_id","subj":"861","obj":"Tax:9606"},{"id":"A862","pred":"tao:has_database_id","subj":"862","obj":"Tax:2697049"},{"id":"A863","pred":"tao:has_database_id","subj":"863","obj":"MESH:D007239"},{"id":"A868","pred":"tao:has_database_id","subj":"868","obj":"Gene:929"},{"id":"A869","pred":"tao:has_database_id","subj":"869","obj":"Tax:9606"},{"id":"A870","pred":"tao:has_database_id","subj":"870","obj":"Tax:2697049"},{"id":"A871","pred":"tao:has_database_id","subj":"871","obj":"MESH:D007239"},{"id":"A878","pred":"tao:has_database_id","subj":"878","obj":"Gene:929"},{"id":"A879","pred":"tao:has_database_id","subj":"879","obj":"Gene:3569"},{"id":"A880","pred":"tao:has_database_id","subj":"880","obj":"Tax:9606"},{"id":"A881","pred":"tao:has_database_id","subj":"881","obj":"Tax:2697049"},{"id":"A882","pred":"tao:has_database_id","subj":"882","obj":"MESH:C502936"},{"id":"A883","pred":"tao:has_database_id","subj":"883","obj":"MESH:D007239"},{"id":"A890","pred":"tao:has_database_id","subj":"890","obj":"Gene:929"},{"id":"A891","pred":"tao:has_database_id","subj":"891","obj":"Gene:3569"},{"id":"A892","pred":"tao:has_database_id","subj":"892","obj":"Tax:9606"},{"id":"A893","pred":"tao:has_database_id","subj":"893","obj":"Tax:2697049"},{"id":"A894","pred":"tao:has_database_id","subj":"894","obj":"MESH:C502936"},{"id":"A895","pred":"tao:has_database_id","subj":"895","obj":"MESH:D007239"},{"id":"A898","pred":"tao:has_database_id","subj":"898","obj":"Tax:9606"},{"id":"A899","pred":"tao:has_database_id","subj":"899","obj":"MESH:C502936"},{"id":"A906","pred":"tao:has_database_id","subj":"906","obj":"Gene:3569"},{"id":"A907","pred":"tao:has_database_id","subj":"907","obj":"Gene:929"},{"id":"A908","pred":"tao:has_database_id","subj":"908","obj":"Gene:920"},{"id":"A909","pred":"tao:has_database_id","subj":"909","obj":"Tax:9606"},{"id":"A910","pred":"tao:has_database_id","subj":"910","obj":"Tax:2697049"},{"id":"A911","pred":"tao:has_database_id","subj":"911","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Figure 5 Immune Dysregulation Caused by SARS-CoV-2 Is Mediated by IL-6\n(A) Negative correlation between serum amounts of IL-6 and the absolute numbers of the mHLA-DR on CD14 monocytes. The Spearman’s (rs) co-efficient of correlation and the respective p value are provided.\n(B) Correlation between the absolute lymphocyte count and the absolute numbers of mHLA-DR on CD14 monocytes. The rs co-efficient of correlation and the respective p value are provided.\n(C) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(D) Changes of the MFI of HLA-DR on CD14 monocytes of four patients infected by SARS-CoV-2 with intermediate state of immune activation after incubation with medium and their plasma.\n(E) Changes of the absolute numbers of mHLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker Tocilizumab is also shown.\n(F) Changes of the MFI of HLA-DR on CD14 monocytes of eight patients infected by SARS-CoV-2 with immune dysregulation after incubation with medium and their plasma; modulation by the addition of the specific IL-6 blocker tocilizumab is also shown.\n(G) Changes of the absolute lymphocyte count of six patients before and after start of treatment with Tocilizumab.\n(H) Intracellular staining for IL-6 in CD14 monocytes and in CD4 lymphocytes of three patients infected by SARS-CoV-2 with immune dysregulation.\nStatistical comparisons are indicated by the arrows; ns: non-significant; ∗p \u003c 0.05; ∗∗p \u003c 0.01."}